선택적 제품 분석
허용하는 경우 개인정보 보호를 고려한 제한적 분석을 사용해 어떤 리서치 여정이 효과적인지 파악합니다. 광고 추적기나 세션 녹화는 사용하지 않습니다. 환경설정에서 이 선택을 변경할 수 있습니다. 자세한 내용은 개인정보 처리방침.
Risk: Regulatory pricing pressures remain the primary headwind, though offset by durable scale advantages.
Valuation: Shares are undervalued, supported by a $226.02 composite midpoint tightly aligned with the $223.25 internal valuation cross-checks.
Quest Diagnostics is a mature, highly cash-generative leader in the US diagnostic testing market. Its robust national network provides durable scale advantages, supporting consistent free cash flow generation and a reliable, growing dividend. With an implied ~19.4x forward P/E, DGX is positioned as a defensive healthcare compounding asset.
Quest Diagnostics is a mature, highly cash-generative leader in the US diagnostic testing market. Its robust national network provides durable scale advantages, supporting consistent free cash flow generation and a reliable, growing dividend. With an implied ~19.4x forward P/E, DGX is positioned as a defensive healthcare compounding asset.
Unmatched national laboratory network lowers per-test processing costs.
Deep integration with hospital IT systems and payer networks.
Valuation: Shares are undervalued, supported by a $226.02 composite midpoint tightly aligned with the $223.25 internal valuation cross-checks.
Buy. Shares trade at a discount to our $226.02 fair value midpoint, offering defensive compounding and structural free cash flow yield.
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
A combined scenario of PAMA reimbursement cuts and labor inflation tests the margin structure. The model withstands moderate pressure given scale efficiencies, but operating margins structurally compressing below 13.0% would invalidate the current valuation.
Reimbursement pressure from PAMA regulations, increased competition from specialized upstarts, and lower routine testing volumes compress margins and stunt long-term cash flow generation.
Aggressive legislative changes to PAMA cause unexpected, steep cuts to clinical lab fee schedules, significantly compressing gross margins.
Technological advancements enable hospitals to profitably internalize testing, shrinking the addressable outsourced laboratory market.
투자 논리를 약화시킬 수 있는 다섯 가지 변화입니다.
A healthy operating cash conversion multiple confirms that diagnostic testing billings convert into real liquidity. Declining conversion metrics signal customer collection challenges or unbilled revenue buildup, constraining organic cash available for debt service and dividend distributions.
현재:1.901 as of the 2026-05-13 analysis date
다음이면 경고Falls below 1.5x over any trailing twelve-month period
Scale Advantage: Unmatched national laboratory network lowers per-test processing costs.
Switching Costs: Deep integration with hospital IT systems and payer networks.
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward path, then discount that future share value back to the analysis date.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $1.3B after capex $496.6M, with terminal value at 70.6% of enterprise value. No FCF cliff is projected unless capex/revenue or gross margin materially resets.
Accretive hospital lab system acquisitions, expansion in advanced and esoteric testing (e.g., Alzheimer's, cancer), and continued realization of cost synergies lead to margin expansion and faster-than-expected organic growth.
If operating margins exceed 14.5%, the bull case is strengthened. If margins compress below 13.0%, review the thesis for structural deterioration.
If operating margins exceed 14.5%, the bull case is strengthened. If margins compress below 13.0%, review the thesis for structural deterioration.
If operating margins exceed 14.5%, the bull case is strengthened. If margins compress below 13.0%, review the thesis for structural deterioration.
If operating margins exceed 14.5%, the bull case is strengthened. If margins compress below 13.0%, review the thesis for structural deterioration.
Warning level: Falls below 1.5x over any trailing twelve-month period. A healthy operating cash conversion multiple confirms that diagnostic testing billings convert into real liquidity. Declining conversion metrics signal customer collection challenges or unbilled revenue buildup, constraining organic cash available for debt service and dividend distributions.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| 매출 | 11,035,000,000 |
|---|---|
| 매출원가 | 7,370,000,000 |
| 매출총이익 | 3,665,000,000 |
| 영업비용 | 2,109,000,000 |
| 영업이익 | 1,556,000,000 |
| 영업외 항목 및 세금 | -564,000,000 |
| 순이익 | 992,000,000 |
| 총자산 | 16,225,000,000 |
|---|---|
| 현금 | 420,000,000 |
| 유동자산 | 2,378,000,000 |
| 총부채 | 8,939,000,000 |
| 유동부채 | 2,278,000,000 |
| 주주자본 | 7,170,000,000 |
2026-05-13 분석에 사용된 시점 재무 데이터입니다.
| 기간 | 매출 | EBITDA | 순이익 | 영업 현금흐름 | 잉여 현금흐름 | 자본적 지출 | 감가상각비 | 주식 기반 보상 | 자사주 매입 | 지급 배당금 | 순부채 발행 | 투자 현금흐름 | 재무 현금흐름 | 기초 현금 | 기말 현금 | 현금 및 투자자산 | 총부채 | 영업이익률 | ROIC | WACC | ROIC−WACC 스프레드 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | 107.9억 | 31.6억 | 20억 | 22.3억 | 18.3억 | 4억 | 4.1억 | 7900만 | 22억 | 3.1억 | -200만 | — | — | — | — | 8.7억 | 47.7억 | 22.1% | — | 5.9% | — |
| 2022-12-31 | 98.8억 | 18.2억 | 9.5억 | 17.2억 | 13.1억 | 4억 | 4.4억 | 7700만 | 14.1억 | 3.1억 | -200만 | — | — | — | — | 3.2억 | 47.1억 | 14.4% | — | 7.7% | — |
| 2023-12-31 | 92.5억 | 17.3억 | 8.5억 | 12.7억 | 8.6억 | 4.1억 | 4.4억 | 7700만 | 2.8억 | 3.1억 | 7.5억 | — | — | — | — | 6.9억 | 55억 | 13.6% | — | 7.3% | — |
| 2024-12-31 | 98.7억 | 18.9억 | 8.7억 | 13.3억 | 9.1억 | 4.3억 | 4.9억 | 8800만 | 1.5억 | 3.3억 | 15.4억 | — | — | — | — | 5.5억 | 70.9억 | 13.6% | — | 7.7% | — |
| 2025-12-31 | 110.4억 | 21.7억 | 9.9억 | 18.9억 | 13.6억 | 5.3억 | 5.7억 | 8800만 | 4.5억 | 3.5억 | -6억 | — | — | — | — | 4.2억 | 65.9억 | 14.1% | — | 6.2% | — |
DGX trades at 16.3x forward earnings against a peer median of 18.3x; EV/EBITDA of 12.3x against a peer median of 18.4x; 6 peers.
Heavy, continuous replacement capital expenditure cycle, yet structural depreciation add-backs exceed maintenance capex, ensuring robust free cash flow.
Aging demographics and increased focus on preventative care drive persistent routine testing volume growth.
Regulatory pricing pressure and hospital budget constraints limit realization of test pricing power.
Heavy, continuous replacement capital expenditure cycle, yet structural depreciation add-backs exceed maintenance capex, ensuring robust free cash flow.
Core holding suitable for defensive, income-oriented allocations.
Valuation: Shares are undervalued, supported by a $226.02 composite midpoint tightly aligned with the $223.25 internal valuation cross-checks.
Buy. The valuation synthesis, anchored by FCFF and Forward Earnings, justifies an $226.02 fair value.
Upside case: Risk: Regulatory pricing pressures remain the primary headwind, though offset by durable scale advantages. Downside case: Valuation: Shares are undervalued, supported by a $226.02 composite midpoint tightly aligned with the $223.25 internal valuation cross-checks.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Persistent wage inflation for specialized lab technicians outpaces pricing power, structurally shifting operating margins below 13.0%.
Clinical diagnostic laboratories operate with substantial fixed costs in personnel and regional testing hubs. If specialized technician wage inflation or regulatory reimbursement cuts overwhelm pricing power, operating margins compress, reducing operating profit and lowering returns on invested capital.
현재:14.1% for the period ended 2025-12-31
다음이면 경고Compresses below 13.0% over two consecutive quarters
National health plan contracts provide essential patient access and specimen volume to diagnostic testing networks. Losing in-network status with a major national insurer would direct routine patient testing to competitors, causing immediate revenue loss and severe fixed-cost deleveraging.
현재:11.8% for the period ended 2025-12-31
다음이면 경고Decelerates below 3.0% year-over-year over two consecutive quarters
Specialized molecular and esoteric diagnostics generate significantly higher contribution margins than commoditized routine blood panels. If hospital insourcing or lab reimbursement reductions erode esoteric testing volumes, overall gross margins shrink, impairing overall operating profitability.
현재:33.2% for the period ended 2025-12-31
다음이면 경고Falls below 30.0% over any four-quarter measurement window
Elevated capital spending on laboratory automation or facility footprint expansion without corresponding revenue gains inflates the asset base. Sub-par returns relative to the cost of capital depress valuation multiples and signal inefficient capital redeployment.
현재:9.2% as of the 2026-05-13 analysis date
다음이면 경고Falls below 7.5% over any trailing twelve-month period
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at WACC, then adjust for signed net debt per current share.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
Solve for the growth rate that makes the model value equal the report-date share price.
Quest Diagnostics is a mature, highly cash-generative leader in the US diagnostic testing market. Its robust national network provides durable scale advantages, supporting consistent free cash flow generation and a reliable, growing dividend.
Warning level: Compresses below 13.0% over two consecutive quarters. Clinical diagnostic laboratories operate with substantial fixed costs in personnel and regional testing hubs. If specialized technician wage inflation or regulatory reimbursement cuts overwhelm pricing power, operating margins compress, reducing operating profit and lowering returns on invested capital.
Warning level: Decelerates below 3.0% year-over-year over two consecutive quarters. National health plan contracts provide essential patient access and specimen volume to diagnostic testing networks. Losing in-network status with a major national insurer would direct routine patient testing to competitors, causing immediate revenue loss and severe fixed-cost deleveraging.
Warning level: Falls below 30.0% over any four-quarter measurement window. Specialized molecular and esoteric diagnostics generate significantly higher contribution margins than commoditized routine blood panels. If hospital insourcing or lab reimbursement reductions erode esoteric testing volumes, overall gross margins shrink, impairing overall operating profitability.
Warning level: Falls below 7.5% over any trailing twelve-month period. Elevated capital spending on laboratory automation or facility footprint expansion without corresponding revenue gains inflates the asset base. Sub-par returns relative to the cost of capital depress valuation multiples and signal inefficient capital redeployment.
| 마진 |
|---|
| DGX | Quest Diagnostics Incorporated | $21.1B | 16.3x | 1.9x | 12.3x | — | — |
| TMO | Thermo Fisher Scientific Inc. | 16.6x | 3.7x | 18.4x | 13.5% | 17.9% | |
| DHR | Danaher Corporation | 18.3x | 4.7x | 16.6x | 7.1% | 22.9% | |
| IDXX | IDEXX Laboratories Inc. | 32.4x | 9.5x | 27.8x | 72.9% | 31.8% | |
| WAT | Waters Corporation | 21.2x | 9.1x | 26.8x | 5.2% | 11.7% | |
| A | Agilent Technologies Inc. | 17.2x | 4.5x | 16.9x | 19.9% | 22.9% |
